Barrett›s esophagus: histochemical difference between goblet cells and blue cells
Main Article Content
Keywords
Cross-Sectional Studies, Barrett Esophagus, Alcian Blue, Periodic Acid-Schiff Reaction, Metaplasia
Abstract
Background: Barrett’s esophagus (BE) is the replacement of the usual esophageal mucosa by a simple columnar epithelium with the presence of goblet cells (GC) of intestinal type. It has been related to different risk factors such as gastroesophageal reflux disease (GERD), inappropriate consumption of irritating foods, smoking and overweight. There are CC mimic cells, known as blue cells (BC), which make the diagnosis of BE difficult, due to the lack of a precise definition of the nature and location of the gastroesophageal junction and the microscopic variations in this area.
Objective: To identify morphologically and with histochemical techniques Alcian blue (AA) and periodic acid-Schiff (PAS) between GC and BC.
Material and methods: Retrolective cross-sectional analytical study where 45 samples of patients diagnosed with BE were included.
Results: The morphological characteristics are similar in both cell varieties. PAS staining was 100%, unlike AA staining, with only 16 cases with staining, corresponding to 35.55%.
Conclusions: PAS staining has a high sensitivity and specificity for the identification of GC, this being a fundamental pillar for the correct diagnosis of BE. The presence of BC detected by AA does not exclude the diagnosis of BE, since both cell types can coexist.
References
Sarem M, Martínez F, Salvia M, Corti R. Low-grade dysplasia in Barrett’s esophagus: A problematic diagnosis. Gastroenterol Hepatol. 2022; 45(10): 228-34. doi: 10.1016/j.gastrohep. 2022.10.002.
Valdovinos F, Bernal A, Barreto R, Briseño D, Martínez J, Romano A et al. Barrett’s esophagus: Ten years of experience at a tertiary care hospital center in Mexico. Rev Gastroenterol Mex. 2018;83(1):25-30. doi: 10.1016/j.gastrohep.2022.10.002.
Huerta F, Bielsa M, Remes J, Valdovinos M, Tamayo-de la Cuesta J. Diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico: recomendaciones de la Asociación Mexicana de Gastroenterología. Rev Gastroenterol Mex. 2016;81(4): 208-22. doi: 10.1016/j.rgmx.2016.04.003.
Moinova H, Laframboise T, Lutterbaugh J, Chandar AK, Dumot J, Faulx A et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med. 2018;10:1-11. doi: 10.1126/scitranslmed.aao5848.
Bellizi A, Odze R. Histopathology of Barrett’s esophagus: A review for the practicing gastroenterologist. Techniques in Gastrointestinal Endoscopy. 2010;2:69-81. doi: 10.1016/j. tgie.2010.02.008.
Srivastava A, Appelman H, Goldsmith JD, Davison JM, Hart J, Krasinskas AM. The Use of Ancillary Stains in the Diagnosis of Barrett Esophagus and Barrett Esophagus-associated Dysplasia: Recommendations From the Rodger C. Haggitt Gastrointestinal Pathology Society. Am J Surg Pathol. 2017;41(5):e8- 21. doi: 10.1097/PAS.0000000000000819.
Zhang L, Sun B, Zhou X, Wei Q, Liang S, Luo G, et al. Barrett’s Esophagus and Intestinal Metaplasia. Frontiers in Oncology. Frontiers Media. 2021;11:1-14. doi: 10.3389/fonc.2021.630837.
Tofani C, Gandhi K, Spataro J, Yoo J, Murphy M, Mohan N, et al. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett’s esophagus. United European Gastroenterol J. 2019;7 (2):225-9. doi: 10.1177/2050640618817098.
Elizondo J, Chaverri G, Téllez I. Actualización en Esófago de Barrett. Revista Médica Sinergia. 2019 Dec;4(12):304-14. doi: 10.31434/rms.v4i12.304.
Soto D, Campos I, Vázquez J, Sepulveda A. Riesgo para desarrollar reflujo gastroesofágico severo en neonatos operados de hernia diafragmática congénita. Rev Med Inst Mex Seguro Soc. 2014;52(2):56-61. Disponible en: http://revistamedica. imss.gob.mx/editorial/index.php/revista_medica/article/view/ 775/1321.
Vázquez J, Mercadillo M, Celis J, Navarrete J. Consumo de tabaco en derechohabientes del IMSS. Rev Med Inst Mex Seguro Soc. 2009;47(4):367-76. Disponible en: http://revistamedica. imss.gob.mx/editorial/index.php/revista_medica/article/view/ 1911/2422.
Cruz M, González F, Ayala E, Lidia O, Vargas G, Zarate A et al. Sobrepeso, obesidad, síndrome metabólico e índice cintura/talla en el personal de salud. Rev Med Inst Mex Seguro Soc. 2015;53(1):36-41. Disponible en: http://revistamedica. imss.gob.mx/editorial/index.php/revista_medica/rt/ printerFriendly/52/344.
Signorini F, Viscido G, Bocco M, Obeide L, Moser F. Impact of Gastric Bypass on Erosive Esophagitis and Barret’s Esophagus. Obes Surg. 2020;30(4):1194-9. doi: 10.1007/ s11695-019-04333-1.
Naini B, Souza R, Odze R. Barrett’s esophagus: A comprehensive and contemporary review for pathologists. Am J Surg Pathol. 2016;40(5):e45-66. doi: 10.1097/PAS.0000000000000598.
Yin F, Hernandez D, Lai J, Liu X. Histopathology of Barrett’s Esophagus and Early-Stage Esophageal Adenocarcinoma: An Updated Review. Gastrointestinal Disorders. 2018;1(1):147- 63. doi: 10.3390/gidisord1010011.
Montgomery EA, Canto MI, Srivastava A. Evaluation and reporting of biopsies from the columnar-lined esophagus and gastro-esophageal junction. Ann Diagn Pathol. 2019;39:111-7. doi: 10.1016/j.anndiagpath.2019.02.012.
Tan W, di Pietro M, Fitzgerald R. Past, present and future of Barrett’s oesophagus. European Journal of Surgical Oncology (EJSO). 2017;43(7):1148-60. doi: 10.1016/j.ejso.2017.02.004.
Odze R. Histology of Barrett’s Metaplasia: Do Goblet Cells Matter?, Digestive Diseases and Sciences. Dig Dis Sci. 2018; 63(8):2042-51. doi: 10.1007/s10620-018-5151-z.
Montgomery E, Arnold C, Lam-Himlin D, Salimian K, Waters K. Some observations on Barrett esophagus and associated dysplasia. Annals of Diagnostic Pathology. 2018;39:5-82. doi: 10.1016/j.anndiagpath.2018.09.013.
Lopes C, Pereira J, Hartmann A, Lopes C. Expression of Mucin-2 and correlation with PAS-alcian blue stain in Barrett’s esophagus. Hepatogastroenterology. 2006;53(70):511-5. doi: 10.1111/j.1365-2559.2004.01849.x.
Torrado J, Piazuelo B, Ruiz I, Izarzugaza M, Constanza Camargo M, Delgado A, et al. El fenotipo de las mucinas en el esófago de Barrett: Mucin phenotypes in Barrett’s esophagus. Revista Española de Patología. 2010;43(1):8-15. doi: 10.1016/j.patol.2010.02.001.
Won-Tak C, Lauwer G, Montgomery E. Utility of ancillary studies in the diagnosis and risk assessment of Barrett’s esophagus and dysplasia. Modern Pathology. 2022;35:1000-12. doi: 10.1038/s41379-022-01056-0.
Kong J, Crissey M, Funakoshi S, Kreindler J, Lynch J. Ectopic Cdx2 expression in murine esophagus models an intermediate stage in the emergence of Barrett’s esophagus. PLoS One. 2011;6(4): 1-12. doi: 10.1371/journal.pone.0018280.
Johnson D, Abdelbaqui M, Tahmasbi M, Mayer Z, Lee H, Malafa MP et al. CDX2 protein expression compared to alcian blue staining in the evaluation of esophageal intestinal metaplasia. World J Gastroenterol. 2015;21(9):2770-6. doi: 10.3748/wjg. v21.i9.2770.
Shaheen N, Falk G, Iyer P, Gerson L. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. American Journal of Gastroenterology. 2016;111(1):30-50. doi: 10.1038/ ajg.2015.322.
Tamayo J. Esófago de Barrett (Actualidades en el diagnóstico y tratamiento). Rev Gastroenterol Mex. 2013;67(1):42-8. doi: 10.1016/j.rgmx.2013.06.020.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.